Biohaven's troriluzole advances past interim futility analysis in phase 2/3 alzheimer's disease study

Biohaven's troriluzole successfully advances past interim futility analysis in pivotal phase 2/3 alzheimer's disease study.biohaven pharmaceutical holding co - dsmb completed its review of prespecified interim futility analysis and communicated that futility was not met.biohaven pharmaceutical - co is encouraged by advancing past prespecified futility criteria after first 100 patients completed 6 months of treatment.
BHVN Ratings Summary
BHVN Quant Ranking